The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the multidrug resistance-associated ATP-binding cassette transporter ABCG2

Ponatinib is a novel tyrosine kinase inhibitor with potent activity against BCR-ABL with mutations including T315I, and also against fms-like tyrosine kinase 3 (FLT3). We tested interactions between ponatinib at pharmacologically relevant concentrations of 50 to 200 nM and the multidrug resistance-a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sen, Rupashree, Natarajan, Karthika, Bhullar, Jasjeet, Shukla, Suneet, Fang, Hong-Bin, Cai, Ling, Chen, Zhe-Sheng, Ambudkar, Suresh V., Baer, Maria R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3683995/
https://ncbi.nlm.nih.gov/pubmed/22778153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-0302
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados